Mesalamine by Zydus Pharmaceuticals (USA) Inc. / Cadila Healthcare Limited MESALAMINE suppository

Mesalamine by

Drug Labeling and Warnings

Mesalamine by is a Prescription medication manufactured, distributed, or labeled by Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Mesalamine suppositories are indicated in adults for the treatment of mildly to moderately active ulcerative proctitis.

  • 2 DOSAGE AND ADMINISTRATION

    Dosage

    The recommended dosage of mesalamine suppositories in adult is 1000 mg administered rectally once daily at bedtime for 3 to 6 weeks depending on symptoms and sigmoidoscopic findings. Safety and effectiveness of mesalamine suppositories beyond 6 weeks have not been established.

    Administration Instructions

    •   Evaluate renal function prior to initiation of mesalamine suppository therapy and periodically while on therapy.
    •   Do not cut or break the suppository.
    •   Retain the suppository for one to three hours or longer, if possible.
    •   If a dose of mesalamine suppository is missed, administer as soon as possible, unless it is almost time for next dose. Do not use two mesalamine suppositories at the same time to make up for a missed dose.
    •   Mesalamine suppositories will cause staining of direct contact surfaces, including but not limited to fabrics, flooring, painted surfaces, marble, granite, vinyl, and enamel. Keep mesalamine suppositories away from these surfaces to prevent staining.
  • 3 DOSAGE FORMS AND STRENGTHS

    Mesalamine suppositories, 1000 mg are off white to light tan colored bullet shaped suppositories.

  • 4 CONTRAINDICATIONS

    Mesalamine suppositories are contraindicated in patients with known or suspected hypersensitivity to salicylates or aminosalicylates or to any ingredients in the suppository vehicle [see Warnings and Precautions (5.3), Adverse Reactions (6.2), and Description (11)].

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Renal Impairment

    Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and renal failure, has been reported in patients given products such as mesalamine suppositories that contain mesalamine or are converted to mesalamine. [see Adverse Reactions (6.2)]

    Evaluate renal function prior to initiation of mesalamine suppository therapy and periodically while on therapy.

    Evaluate the risks and benefits of using mesalamine suppositories in patients with known renal impairment or a history of renal disease or taking concomitant nephrotoxic drugs. In animal studies, the kidney was the principal organ for toxicity [see Drug Interactions (7.1), Use in Specific Populations (8.6) and Nonclinical Toxicology (13.2)].

    5.2 Mesalamine-Induced Acute Intolerance Syndrome

    Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from an exacerbation of ulcerative colitis. Although the exact frequency of occurrence has not been determined, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine. Symptoms include cramping, acute abdominal pain and bloody diarrhea, and sometimes fever, headache, and rash. Monitor patients for worsening of these symptoms while on treatment. If acute intolerance syndrome is suspected, promptly discontinue treatment with mesalamine suppositories.

    5.3 Hypersensitivity Reactions

    Hypersensitivity reactions have been reported in patients taking sulfasalazine. Some patients may have a similar reaction to mesalamine suppository or to other compounds that contain or are converted to mesalamine.

    As with sulfasalazine, mesalamine-induced hypersensitivity reactions may present as internal organ involvement, including myocarditis, pericarditis, nephritis, hepatitis, pneumonitis and hematologic abnormalities. Evaluate patients immediately if signs or symptoms of a hypersensitivity reaction are present. Discontinue mesalamine suppository if an alternative etiology for the signs and symptoms cannot be established.

    5.4 Hepatic Failure

    There have been reports of hepatic failure in patients with pre-existing liver disease who have been administered other products containing mesalamine. Evaluate the risks and benefits of using mesalamine suppositories in patients with known liver impairment.

    5.5 Interaction with Laboratory Test for Urinary Normetanephrine

    Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection, because of the similarity in the chromatograms of normetanephrine and mesalamine's main metabolite, N-acetylaminosalicylic acid. Consider an alternative, selective assay for normetanephrine.

  • 6 ADVERSE REACTIONS

    The most serious adverse reactions seen in mesalamine suppositories clinical trials or with other products that contain or are metabolized to mesalamine are:

    • Renal Impairment [see Warnings andPrecautions (5.1)]
    • Mesalamine-Induced Acute Intolerance Syndrome [see Warnings andPrecautions (5.2)]
    • Hypersensitivity Reactions [see Warnings and Precautions (5.3)]
    • Hepatic Failure [see Warnings andPrecautions (5.4)]

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    The most common adverse reactions in adult patients with mildly to moderately active ulcerative proctitis in double-blind, placebo-controlled trials are summarized in the Table 1 below.

    Table 1Adverse Reactions Occurring In More Than 1% of Mesalamine Suppository Treated Patients (Comparison to Placebo)
    Symptom
    		Mesalamine
    		(n = 177)
    		Placebo
    		(n = 84)

    		N
    		%
    		N
    		%
    Dizziness
    		5
    		3
    		2
    		2.4
    Rectal Pain
    		3
    		1.8
    		0
    		0
    Fever
    		2
    		1.2
    		0
    		0
    Rash
    		2
    		1.2
    		0
    		0
    Acne
    		2
    		1.2
    		0
    		0
    Colitis
    		2
    		1.2
    		0
    		0

    In a multicenter, open-label, randomized, parallel group study in 99 patients comparing the mesalamine, 1000 mg suppository administered nightly to that of the mesalamine, 500 mg suppository twice daily. The most common adverse reactions in both groups were headache (14%), flatulence (5%), abdominal pain (5%), diarrhea (3%), and nausea (3%). Three (3) patients discontinued medication because of an adverse reaction; one of these adverse reactions (headache) was deemed possibly related to study medication. The recommended dosage of mesalamine suppository is 1000 mg administered rectally once daily at bedtime [see Dosage and Administration (2)].

    6.2 Postmarketing Experience

    In addition to the adverse reactions reported above in clinical trials involving mesalamine suppositories, the adverse reactions listed below have been identified during post-approval use of mesalamine suppositories and other mesalamine-containing products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    •   Body  as  a  Whole:  drug  fever,  fatigue,  lupus-like  syndrome, medication residue
    •   Cardiac Disorders: myocarditis, pericarditis, pericardial effusion [see Warnings and Precautions (5.3)]
    •   Endocrine : Nephrogenic diabetes insipidus
    •   Eye disorders : eye swelling
    •   Gastrointestinal    Disorders :    abdominal    cramps,    abdominal distension, anal pruritus, anorectal discomfort, constipation, feces discolored, flatulence, frequent bowel movements, gastrointestinal bleeding, mucus stools, nausea, painful defecation, pancreatitis, proctalgia, rectal discharge, rectal tenesmus, stomach discomfort, vomiting
    •   Hepatic   Disorders:   cholestatic   jaundice,   hepatitis,   jaundice, Kawasaki-like syndrome including changes in liver enzymes, liver necrosis, liver failure
    •   Hematologic    Disorders:    agranulocytosis,    aplastic    anemia, thrombocytopenia
    •   Neurological/Psychiatric  Disorders:   Guillain-Barre   syndrome, peripheral neuropathy, transverse myelitis, intracranial hypertension
    •   Renal Disorders: interstitial nephritis, renal failure, minimal change nephropathy [see Warnings and Precautions (5.1)]
    •   Respiratory, Thoracic and Mediastinal Disorders: hypersensitivity pneumonitis (including allergic alveolitis, eosinophilic pneumonitis, interstitial pneumonitis)
    •   Skin and Subcutaneous Tissue Disorder: alopecia, erythema, erythema nodosum, pruritus, psoriasis, pyoderma gangrenosum, urticaria
    •   Urogenital: reversible oligospermia
  • 7 DRUG INTERACTIONS

    7.1 Nephrotoxic Agents, Including Non-Steroidal Anti-Inflammatory Drugs

    The concurrent use of mesalamine with known nephrotoxic agents, including nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of nephrotoxicity. Monitor patients taking nephrotoxic drugs for changes in renal function and mesalamine-related adverse reactions [see Warnings and Precautions (5.1)].

    7.2 Azathioprine or 6-Mercaptopurine

    The concurrent use of mesalamine with azathioprine or 6-mercaptopurine may increase the risk for blood disorders. If concomitant use of mesalamine suppositories and azathioprine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts.

    7.3 Urinary NormetanephrineMeasurements

    Use of mesalamine may lead to spuriously elevated test results when measuring urinary normetanephrine by liquid chromatography with electrochemical detection, because of the similarity in the chromatograms of normetanephrine and mesalamine's main metabolite, N-acetylaminosalicylic acid. Consider an alternative, selective assay for normetanephrine [see Warnings and Precautions (5.5)].

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Limited published data on mesalamine use in pregnant women are insufficient to inform a drug-associated risk. No evidence of teratogenicity was observed in rats or rabbits when treated during gestation with orally administered mesalamine at doses greater than the recommended human intra-rectal dose [see Data].

    The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    Data

    Animal Data

    Reproduction studies have been performed in rats at oral doses up to 320 mg/kg/day (about 1.7 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area) and in rabbits at oral doses up to 495 mg/kg/day (about 5.4 times the recommended human intra- rectal dose of mesalamine suppositories, based on body surface area) following administration during the period of organogenesis and have revealed no evidence of impaired fertility or harm to the fetus due to mesalamine.

    8.2 Lactation

    Risk Summary

    Mesalamine and its N-acetyl metabolite are present in human milk in undetectable to small amounts [see Data]. There are limited reports of diarrhea in breastfed infants. There is no information on the effects of the drug on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of mesalamine suppositories to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for mesalamine suppositories and any potential adverse effects on the breastfed child from mesalamine suppositories or from the underlying maternal conditions.

    Clinical Considerations

    Monitor breastfed infants for diarrhea.

    Data

    In published lactation studies, maternal mesalamine doses from various oral and rectal formulations and products ranged from 500 mg to 3 g daily. The concentration of mesalamine in milk ranged from non-detectable to 0.11 mg/L. The concentration of the N-acetyl-5aminosalicylic acid metabolite ranged from 5 to 18.1 mg/L. Based on these concentrations, estimated infant daily dosages for an exclusively breastfed infant are 0 to 0.017 mg/kg/day of mesalamine and 0.75 to 2.72 mg/kg/day of N-acetyl-5-aminosalicylic acid.

    8.4 Pediatric Use

    The safety and effectiveness of mesalamine suppositories in pediatric patients for the treatment of mildly to moderately active ulcerative proctitis have not been established. Mesalamine suppositories were evaluated for the treatment of ulcerative proctitis in a 6-week, open-label, single-arm study in 49 patients 5 to 17 years of age, which only included 14 patients with histologically-confirmed cases of ulcerative proctitis. However, efficacy was not demonstrated. Adverse reactions seen in pediatric patients in this trial (abdominal pain, headache, pyrexia, pharyngolaryngeal pain, diarrhea and vomiting) were similar to those seen in adult patients.

    8.5 Geriatric Use

    Clinical trials of mesalamine suppositories did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Systemic exposures are increased in elderly subjects [See Clinical Pharmacology (12.3)]. Reports from uncontrolled clinical studies and postmarketing reporting systems suggested a higher incidence of blood dyscrasias (i.e., agranulocytosis, neutropenia and pancytopenia) in patients receiving mesalamine-containing products such as mesalamine who were 65 years or older compared to younger patients. Monitor complete blood cell counts and platelet counts in elderly patients during treatment with mesalamine suppositories. In general, the greater frequency of decreased hepatic, renal, or cardiac function, and of concurrent disease or other drug therapy in elderly patients should be considered when prescribing mesalamine suppositories [see Use in Specific Populations (8.6)].

    8.6 Renal Impairment

    Mesalamine is known to be substantially excreted by the kidney, and the risk of adverse reactions may be greater in patients with impaired renal function. Evaluate renal function in all patients prior to initiation and periodically while on mesalamine suppository therapy. Monitor patients with known renal impairment or history of renal disease or taking nephrotoxic drugs for decreased renal function and mesalamine-related adverse reactions [see Warnings and Precautions (5.1), Drug Interactions (7.1) and Adverse Reactions (6.2)].

  • 10 OVERDOSAGE

    There have been no documented reports of serious toxicity in man resulting from massive overdosing with mesalamine suppositories. Under ordinary circumstances, mesalamine absorption from the colon is limited.

  • 11 DESCRIPTION

    The active ingredient in mesalamine suppositories, 1000 mg is mesalamine, also known as mesalazine or 5-aminosalicylic acid (5-ASA). Chemically, mesalamine is 5-amino-2-hydroxybenzoic acid, and is classified as an anti-inflammatory drug. Each mesalamine suppository contains 1000 mg of mesalamine, USP (micronized) in a base of hard fat.

    Mesalamine, USP (micronized) are light tan to pink colored, needle-shaped crystals. Color may darken on exposure to air. It is odorless or may have a slight characteristic odor. It is slightly soluble in water; very slightly soluble in methanol, in dehydrated alcohol, and in acetone; practically insoluble in n-butyl alcohol, in chloroform, in ether, in ethyl acetate, in n-hexane, in methylene chloride, and in n-propyl alcohol; soluble in dilute hydrochloric acid and in dilute alkali hydroxides.

    The molecular formula is C7H7NO3, representing a molecular weight of 153.14. The structural formula is:

    Mesalamine rectal suppository
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The mechanism of action of mesalamine is not fully understood, but appears to be topical rather than systemic. Although the pathology of inflammatory bowel disease is uncertain, both prostaglandins and leukotrienes have been implicated as mediators of mucosal injury and inflammation.

    12.3 Pharmacokinetics

    Absorption

    Mesalamine (5-ASA) administered as a rectal suppository is variably absorbed. In patients with ulcerative colitis treated with mesalamine 500 mg rectal suppositories, administered once every eight hours for six days, the mean mesalamine peak plasma concentration (Cmax) was 353 ng/mL (CV=55%) following the initial dose and 361 ng/mL (CV=67%) at steady state. The mean minimum steady state plasma concentration (Cmin) was 89 ng/mL (CV=89%). Absorbed mesalamine does not accumulate in the plasma.

    Distribution

    Mesalamine administered as a rectal suppository distributes in rectal tissue to some extent.

    Elimination

    In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, the mean elimination half-life was 5 hours (CV=73%) for 5-ASA and 5 hours (CV=63%) for N-acetyl-5-ASA, the active metabolite, following the initial dose. At steady state, the mean elimination half-life was 7 hours for both 5-ASA and N-acetyl-5-ASA (CV=102% for 5-ASA and 82% for N-acetyl-5-ASA).

    Metabolism

    The absorbed mesalamine is extensively metabolized, mainly to N-acetyl-5-ASA in the liver and in the gut mucosal wall. In patients with ulcerative colitis treated with one mesalamine 500 mg rectal suppository every eight hours for six days, the peak concentration (Cmax) of N-acetyl-5-ASA ranged from 467 ng/mL to 1399 ng/mL following the initial dose and from 193 ng/mL to 1304 ng/mL at steady state.

    Excretion

    Mesalamine is eliminated from plasma mainly by urinary excretion, predominantly as N-acetyl-5-ASA. In patients with ulcerative proctitis treated with mesalamine 500 mg as a rectal suppository every 8 hours for 6 days, 12% or less of the dose was eliminated in urine as unchanged 5-ASA and 8% to 77% was eliminated as N-acetyl-5-ASA following the initial dose. At steady state, 11% or less of the dose was eliminated in the urine as unchanged 5-ASA and 3% to 35% was eliminated as N-acetyl-5-ASA.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Mesalamine caused no increase in the incidence of neoplastic lesions over controls in a two-year study of Wistar rats fed up to 320 mg/kg/day of mesalamine admixed with diet (about 1.7 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area).

    Mesalamine was not mutagenic in the Ames test, the mouse lymphoma cell (TK+/-) forward mutation test, or the mouse micronucleus test.

    No effects on fertility or reproductive performance of the male and female rats were observed at oral mesalamine doses up to 320 mg/kg/day (about 1.7 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area).

    13.2 Animal Toxicology and/or Pharmacology

    Toxicology studies of mesalamine were conducted in rats, mice, rabbits and dogs, and the kidney was the main target organ of toxicity. In rats, adverse renal effects were observed at a single oral dose of 600 mg/kg (about 3.2 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area) and at intravenous doses of >214 mg/kg (about 1.2 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area). In a 13-week oral gavage toxicity study in rats, papillary necrosis and/or multifocal tubular injury were observed in males receiving 160 mg/kg (about 0.86 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area) and in both males and females at 640 mg/kg (about 3.5 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area). In a combined 52-week toxicity and 127-week carcinogenicity study in rats, degeneration of the kidneys and hyalinization of basement membranes and Bowman's capsule were observed at oral doses of 100 mg/kg/day (about 0.54 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area) and above. In a 14-day rectal toxicity study of mesalamine suppositories in rabbits, intra-rectal doses up to 800 mg/kg (about 8.6 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area) was not associated with any adverse effects. In a six-month oral toxicity study in dogs, doses of 80 mg/kg (about 1.4 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area) and higher caused renal pathology similar to that described for the rat. In a rectal toxicity study of mesalamine suppositories in dogs, a dose of 166.6 mg/kg (about 3 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area) produced chronic nephritis and pyelitis. In the 12-month eye toxicity study in dogs, keratoconjunctivitis sicca (KCS) occurred at oral doses of 40 mg/kg (about 0.72 times the recommended human intra-rectal dose of mesalamine suppositories, based on body surface area) and above.

  • 14 CLINICAL STUDIES

    Two double-blind, placebo-controlled, multicenter trials of mesalamine suppositories were conducted in North America in adult patients with mildly to moderately active ulcerative proctitis. The regimen in Study 1 was a 500 mg mesalamine suppository administered rectally three times daily and in Study 2 was a 500 mg mesalamine suppository administered rectally twice daily. In both trials, patients had an average extent of proctitis (upper disease boundary) of approximately 10 cm and approximately 80% of patients had multiple prior episodes of proctitis. A total of 173 patients were evaluated (Study 1, N=79; Study 2, N=94), of which 89 patients received mesalamine, and 84 patients received placebo. The mean age of patients was 39 years (range 17 to 73 years), 60% were female, and 97% were white.

    The primary measures of efficacy were clinical disease activity index (DAI) and histologic evaluations in both trials. The DAI is a composite index reflecting rectal bleeding, stool frequency, mucosal appearance at endoscopy, and a physician's global assessment of disease. Patients were evaluated clinically and sigmoidoscopically after 3 and 6 weeks of treatment.

    Compared to placebo, mesalamine suppositories were statistically (p<0.01) superior to placebo in both trials with respect to improvement in stool frequency, rectal bleeding, mucosal appearance, disease severity, and overall disease activity after 3 and 6 weeks of treatment. The effectiveness of mesalamine suppositories was statistically significant irrespective of sex, extent of proctitis, duration of current episode, or duration of disease.

    An additional multicenter, open-label, randomized, parallel group study in 99 patients diagnosed with mildly to moderately ulcerative proctitis compared 1000 mg mesalamine suppositories administered rectally once daily at bedtime (N=35) to 500 mg mesalamine suppository administered rectally twice daily, in the morning and at bedtime (N=46), for 6 weeks.

    The primary measures of efficacy included the clinical disease activity index (DAI) and histologic evaluations. Patients were evaluated clinically and sigmoidoscopically at 3 and 6 weeks of treatment.

    The efficacy at 6 weeks was not different between the treatment groups. Both were effective in the treatment of ulcerative proctitis and resulted in a significant decrease at 6 weeks in DAI: in the mesalamine 500 mg twice daily group, the mean DAI value decreased from 6.6 to 1.6, and in the 1000 mg at bedtime group, the mean DAI value decreased from 6.2 to 1.3, which represents a decrease of greater than 75% in both groups. After 6 weeks of treatment, a DAI score of less than 3 was achieved in 78% of patients in the mesalamine 500 mg twice daily group and 86% of patients in the mesalamine suppositories, 1000 mg once daily group. The recommended dosage of mesalamine suppositories 1000 mg is administered rectally once daily at bedtime [see Dosage and Administration (2)].

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Mesalamine suppositories for rectal administration are off white to light tan colored bullet shaped suppository and are supplied as:

    NDC: 70710-1302-7 in cartons of 30 rectal suppositories (5 x 6's individually plastic wrapped suppositories in aluminum pouch)

    Store below 25°C (77°F), may be refrigerated. Keep away from direct heat, light or humidity.

  • 17 PATIENT COUNSELING INFORMATION

    Advise patients to read the FDA-approved patient labeling (Patient Information)

    Administration

    Advise patients

    • Do not cut or break the suppository.
    • Retain the suppository for one to three hours or longer, if possible.
    • If a dose of mesalamine suppository is missed, administer as soon as possible, unless it is almost time for next dose. Do not use two mesalamine suppositories at the same time to make up for a missed dose.
    • Mesalamine suppositories will cause staining of direct contact surfaces, including but not limited to fabrics, flooring, painted surfaces, marble, granite, vinyl, and enamel. Keep mesalamine suppositories away from these surfaces to prevent staining.

    Renal Impairment

    Inform patients that mesalamine suppositories may decrease their renal function, especially if they have known renal impairment or are taking nephrotoxic drugs, including NSAIDs, and periodic monitoring of renal function will be performed while they are on therapy. Advise patients to complete all blood tests ordered by their healthcare provider [see Warnings and Precautions (5.1), Drug Interactions (7.1)].

    Mesalamine-Induced Acute Intolerance Syndrome and Other Hypersensitivity Reactions

    Inform patients of the signs and symptoms of hypersensitivity reactions. Instruct patients to stop taking mesalamine suppositories and report to their healthcare provider if they experience new or worsening symptoms Acute Intolerance Syndrome (cramping, abdominal pain, bloody diarrhea, fever, headache, and rash) or other symptoms suggestive of mesalamine-induced hypersensitivity [see Warnings and Precautions (5.2, 5.3)].

    Hepatic Failure

    Inform patients with known liver disease of the signs and symptoms of worsening liver function and advise them to report to their healthcare provider if they experience such signs or symptoms [see Warnings and Precautions (5.4)].

    Blood Disorders

    Inform elderly patients and those taking azathioprine or 6-mercaptopurine of the risk for blood disorders and the need for periodic monitoring of complete blood cell counts and platelet counts while on therapy. Advise patients to complete all blood tests ordered by their healthcare provider [see Drug Interactions (7.2), Use in Specific Populations (8.5)].

  • SPL UNCLASSIFIED SECTION

    Manufactured by:

    Cadila Healthcare Limited

    Changodar, Ahmedabad, India.

    Distributed by:

    Zydus Pharmaceuticals (USA) Inc.

    Pennington, NJ 08534

    Rev.: 09/19

  • SPL UNCLASSIFIED SECTION

    FDA-Approved Patient Labeling

    Patient Information

    Mesalamine (me-SAL-a-meen) suppositories, for rectal use

    What are mesalamine suppositories?

    Mesalamine suppositories are a prescription medicine used to treat adults with active ulcerative proctitis (ulcerative rectal colitis).

    It is not known if mesalamine suppositories are safe and effective in children.

    Do not use mesalamine suppositories if you are:

    • allergic to medicines that contain salicylates, including aspirin.
    • allergic to mesalamine or any of the ingredients in mesalamine suppositories. See the end of this Patient Information leaflet for a complete list of ingredients in mesalamine suppositories.

    Ask your doctor if you are not sure if your medicine is listed above.

    Before using mesalamine suppositories, tell your doctor if you:

    • have a history of allergic reaction to the medicine sulfasalazine (Azulfidine).
    • have kidney problems.
    • have ever had inflammation of the sac around your heart (pericarditis).
    • have liver problems.
    • have any other medical conditions.
    • are pregnant or plan to become pregnant. It is not known if mesalamine suppositories can harm your unborn baby.
    • are breastfeeding or plan to breastfeed. Mesalamine can pass into your breast milk. Talk to your doctor about the best way to feed your baby if you use mesalamine suppositories.

    Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

    Using mesalamine suppositories with certain other medicines may affect each other. Using mesalamine suppositories with other medicines can cause serious side effects.

    Especially tell your doctor if you take nonsteroidal anti-inflammatory drugs (NSAIDS), or medicines that contain azathioprine or 6-mercaptopurine. Taking mesalamine suppositories with NSAIDS may cause kidney problems. Taking mesalamine suppositories with azathioprine or 6-mercaptopurine may cause blood problems. You doctor may do certain tests during treatment with mesalamine suppositories.

    Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

    How should I use mesalamine suppositories?

    • Use mesalamine suppositories exactly as prescribed by your doctor. Your doctor will tell you how long to continue using mesalamine suppositories.
    • Mesalamine suppositories come as a suppository that you insert into your rectum.
    • Do not cut or break the suppository.
    • Use mesalamine suppositories 1 time each day at bedtime, for 3 to 6 weeks. It is not known if mesalamine suppositories are safe and effective for use for longer than 6 weeks.
    • After you insert mesalamine suppositories in your rectum, try to keep (retain) the suppository in your rectum for 1 to 3 hours or longer if possible.
    • If you miss a dose of mesalamine suppositories, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses at the same time.
    • Mesalamine suppositories can stain surfaces including, clothing and other fabrics, flooring, painted surfaces, marble, granite, vinyl and enamel. Keep mesalamine suppositories away from these surfaces to prevent staining.

    What are the possible side effects of mesalamine suppositories?

    Mesalamine suppositories may cause serious side effects, including:

    • Kidney problems. Your doctor will do certain tests before you start using mesalamine suppositories and during your treatment with mesalamine suppositories.
    • Acute Intolerance Syndrome or Other Allergic type reactions. Some people who use mesalamine suppositories can have allergic type reactions, including "Acute Intolerance Syndrome." Other allergic reactions can cause heart problems including an inflammation of the sac around the heart (pericarditis), blood problems, and problems with other organs in the body including the kidneys, liver and lungs. These problems usually happen in people who have had an allergic reaction to medicines containing sulfasalazine. Stop using mesalamine suppositories and tell your doctor right away if you get any of these symptoms:
      • cramps
      • stomach (abdominal) pain
      • bloody diarrhea
      • chest pain
      • decrease in the amount of urine
      • fever
      • headache
      • rash
      • shortness of breath
      • fatigue
    • Liver problems. This can happen in people who have a history of liver problems and have taken other medicines that contain mesalamine. Tell your doctor right away if you get any of these symptoms while using mesalamine suppositories:
      • yellowing of your eyes
      • itchy skin
      • flu-like symptoms
      • nausea or vomiting
      • feeling very tired

    The most common side effects of mesalamine suppositories include:

    • dizziness
    • acne
    • inflammation of the large intestine (colitis)
    • rectal pain
    • fever
    • rash

    These are not all of the possible side effects of mesalamine suppositories.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    How should I store mesalamine suppositories?

    • Store mesalamine suppositories below 25°C (77°F), may be refrigerated.
    • Keep mesalamine suppositories away from direct heat, light, or humidity.

    Keep mesalamine suppositories and all medicines out of the reach of children.

    General information about the safe and effective use of mesalamine suppositories.

    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use mesalamine suppositories for a condition for which it was not prescribed. Do not give mesalamine suppositories to other people, even if they have the same symptoms that you have. It may harm them.

    You can ask your doctor or pharmacist for information about mesalamine suppositories that is written for health professionals.

    Please address medical inquiries to, MedicalAffairs@zydususa.com Tel.: 1-877-993-8779.

    What are the ingredients in mesalamine suppositories?

    Active ingredients: mesalamine, USP

    Inactive ingredients: Hard fat base

    This Patient Information has been approved by the U.S. Food and Drug Administration.

  • SPL UNCLASSIFIED SECTION

    Manufactured by:

    Cadila Healthcare Limited

    Changodar, Ahmedabad, India.

    Distributed by:

    Zydus Pharmaceuticals (USA) Inc.

    Pennington, NJ 08534

    Rev.: 09/19

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC: 70710-1302-6

    Mesalamine suppositories, 1000 mg

    30 rectal suppositories

    Rx only

    Zydus

    Mesalamine rectal suppository

    NDC: 70710-1302-7

    Mesalamine rectal suppositories, 1000 mg

    30 rectal suppositories

    Rx only

    Zydus

    Mesalamine rectal suppositories, 1000 mg
  • INGREDIENTS AND APPEARANCE
    MESALAMINE 
    mesalamine suppository
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 70710-1302
    Route of AdministrationRECTAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    MESALAMINE (UNII: 4Q81I59GXC) (MESALAMINE - UNII:4Q81I59GXC) MESALAMINE1000 mg
    Inactive Ingredients
    Ingredient NameStrength
    FAT, HARD (UNII: 8334LX7S21)  
    Product Characteristics
    ColorWHITE (OFF WHITE TO LIGHT TAN COLORED) Score    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 70710-1302-75 in 1 POUCH02/14/2020
    1NDC: 70710-1302-66 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20895302/14/2020
    Labeler - Zydus Pharmaceuticals (USA) Inc. (156861945)
    Registrant - Zydus Pharmaceuticals (USA) Inc. (156861945)
    Establishment
    NameAddressID/FEIBusiness Operations
    Cadila Healthcare Limited650650802ANALYSIS(70710-1302) , MANUFACTURE(70710-1302)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.